Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

[11C]-Labeled Metformin Distribution in the Liver and Small Intestine Using Dynamic Positron Emission Tomography in Mice Demonstrates Tissue-Specific Transporter Dependency

(2016) Jonas B. Jensen et al.   DIABETES

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

(2016) Sweety Agrawal et al.   DIABETES CARE

Metformin and the gastrointestinal tract

(2016) Laura J. McCreight et al.   DIABETOLOGIA

Metformin-associated lactic acidosis: Current perspectives on causes and risk

(2016) Ralph DeFronzo et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Comment on ‘A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure’

(2015) G. C. Jones et al.   DIABETIC MEDICINE

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

(2015) Kristoffer Forslund et al.   NATURE

Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

(2015) Frank A Duca et al.   NATURE MEDICINE

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

(2014) Julie Berg Schmidt et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Taste of a Pill

(2014) Nora Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

(2014) Anila K. Madiraju et al.   NATURE

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

An increase in theAkkermansiaspp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

(2013) Na-Ri Shin et al.   GUT

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment

(2011) Z. Panossian et al.   DIABETOLOGIA

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

(2010) Marc Foretz et al.   JOURNAL OF CLINICAL INVESTIGATION

Metformin and the intestine

(2008) C. J. Bailey et al.   DIABETOLOGIA

Mechanisms Underlying Saturable Intestinal Absorption of Metformin

(2008) W. R. Proctor et al.   DRUG METABOLISM AND DISPOSITION

Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus

(2008) Ying Hong et al.   JOURNAL OF CLINICAL PHARMACOLOGY